Patient-derived xenograft models of ovarian/gynecologic tumors

L. Liang, I. Mercado-Uribe, N. Niu, Y. Jiang, W. Cheng, J. Zhang, Gordon Mills, C. Scott, A. K. Sood, J. Liu

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Patient-derived xenografts (PDXs) have become the most promising preclinical model for gynecologic malignances, especially ovarian cancer. To generate PDX models of ovarian cancer, fresh human tumors have been injected into different sites in mouse models, including the intraovarian bursa, intraperitoneal cavity, subcutaneous tissue, gonadal fat pad, mammary fat pad, and subrenal capsule. The engraftment of first-generation ovarian cancer PDXs usually takes 2-6. months. Success rates for first-generation ovarian cancer PDXs range from 25% to 80%, depending on many factors, including the type of immunocompromised mice, tumor histotypes, and implant sites. The ovarian cancer PDXs have been shown to retain the morphologic, immunophenotypic, and genomic characteristics of original human tumors. Moreover, the predictive value of ovarian cancer PDXs has been proved by recent studies that showed concordance between chemoresponse in tumor xenografts and patients.

Original languageEnglish (US)
Title of host publicationPatient Derived Tumor Xenograft Models
Subtitle of host publicationPromise, Potential and Practice
PublisherElsevier Inc.
Pages257-271
Number of pages15
ISBN (Electronic)9780128040614
ISBN (Print)9780128040102
DOIs
StatePublished - Oct 25 2016
Externally publishedYes

Fingerprint

Heterografts
Ovarian Neoplasms
Neoplasms
Adipose Tissue
Subcutaneous Tissue
Capsules
Breast

Keywords

  • Mouse models
  • Ovarian cancer
  • Patient-derived xenograft
  • Personalized therapy
  • Preclinical models

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Liang, L., Mercado-Uribe, I., Niu, N., Jiang, Y., Cheng, W., Zhang, J., ... Liu, J. (2016). Patient-derived xenograft models of ovarian/gynecologic tumors. In Patient Derived Tumor Xenograft Models: Promise, Potential and Practice (pp. 257-271). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-804010-2.00019-9

Patient-derived xenograft models of ovarian/gynecologic tumors. / Liang, L.; Mercado-Uribe, I.; Niu, N.; Jiang, Y.; Cheng, W.; Zhang, J.; Mills, Gordon; Scott, C.; Sood, A. K.; Liu, J.

Patient Derived Tumor Xenograft Models: Promise, Potential and Practice. Elsevier Inc., 2016. p. 257-271.

Research output: Chapter in Book/Report/Conference proceedingChapter

Liang, L, Mercado-Uribe, I, Niu, N, Jiang, Y, Cheng, W, Zhang, J, Mills, G, Scott, C, Sood, AK & Liu, J 2016, Patient-derived xenograft models of ovarian/gynecologic tumors. in Patient Derived Tumor Xenograft Models: Promise, Potential and Practice. Elsevier Inc., pp. 257-271. https://doi.org/10.1016/B978-0-12-804010-2.00019-9
Liang L, Mercado-Uribe I, Niu N, Jiang Y, Cheng W, Zhang J et al. Patient-derived xenograft models of ovarian/gynecologic tumors. In Patient Derived Tumor Xenograft Models: Promise, Potential and Practice. Elsevier Inc. 2016. p. 257-271 https://doi.org/10.1016/B978-0-12-804010-2.00019-9
Liang, L. ; Mercado-Uribe, I. ; Niu, N. ; Jiang, Y. ; Cheng, W. ; Zhang, J. ; Mills, Gordon ; Scott, C. ; Sood, A. K. ; Liu, J. / Patient-derived xenograft models of ovarian/gynecologic tumors. Patient Derived Tumor Xenograft Models: Promise, Potential and Practice. Elsevier Inc., 2016. pp. 257-271
@inbook{1ac183360ce04bfe941005dd99f7c265,
title = "Patient-derived xenograft models of ovarian/gynecologic tumors",
abstract = "Patient-derived xenografts (PDXs) have become the most promising preclinical model for gynecologic malignances, especially ovarian cancer. To generate PDX models of ovarian cancer, fresh human tumors have been injected into different sites in mouse models, including the intraovarian bursa, intraperitoneal cavity, subcutaneous tissue, gonadal fat pad, mammary fat pad, and subrenal capsule. The engraftment of first-generation ovarian cancer PDXs usually takes 2-6. months. Success rates for first-generation ovarian cancer PDXs range from 25{\%} to 80{\%}, depending on many factors, including the type of immunocompromised mice, tumor histotypes, and implant sites. The ovarian cancer PDXs have been shown to retain the morphologic, immunophenotypic, and genomic characteristics of original human tumors. Moreover, the predictive value of ovarian cancer PDXs has been proved by recent studies that showed concordance between chemoresponse in tumor xenografts and patients.",
keywords = "Mouse models, Ovarian cancer, Patient-derived xenograft, Personalized therapy, Preclinical models",
author = "L. Liang and I. Mercado-Uribe and N. Niu and Y. Jiang and W. Cheng and J. Zhang and Gordon Mills and C. Scott and Sood, {A. K.} and J. Liu",
year = "2016",
month = "10",
day = "25",
doi = "10.1016/B978-0-12-804010-2.00019-9",
language = "English (US)",
isbn = "9780128040102",
pages = "257--271",
booktitle = "Patient Derived Tumor Xenograft Models",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Patient-derived xenograft models of ovarian/gynecologic tumors

AU - Liang, L.

AU - Mercado-Uribe, I.

AU - Niu, N.

AU - Jiang, Y.

AU - Cheng, W.

AU - Zhang, J.

AU - Mills, Gordon

AU - Scott, C.

AU - Sood, A. K.

AU - Liu, J.

PY - 2016/10/25

Y1 - 2016/10/25

N2 - Patient-derived xenografts (PDXs) have become the most promising preclinical model for gynecologic malignances, especially ovarian cancer. To generate PDX models of ovarian cancer, fresh human tumors have been injected into different sites in mouse models, including the intraovarian bursa, intraperitoneal cavity, subcutaneous tissue, gonadal fat pad, mammary fat pad, and subrenal capsule. The engraftment of first-generation ovarian cancer PDXs usually takes 2-6. months. Success rates for first-generation ovarian cancer PDXs range from 25% to 80%, depending on many factors, including the type of immunocompromised mice, tumor histotypes, and implant sites. The ovarian cancer PDXs have been shown to retain the morphologic, immunophenotypic, and genomic characteristics of original human tumors. Moreover, the predictive value of ovarian cancer PDXs has been proved by recent studies that showed concordance between chemoresponse in tumor xenografts and patients.

AB - Patient-derived xenografts (PDXs) have become the most promising preclinical model for gynecologic malignances, especially ovarian cancer. To generate PDX models of ovarian cancer, fresh human tumors have been injected into different sites in mouse models, including the intraovarian bursa, intraperitoneal cavity, subcutaneous tissue, gonadal fat pad, mammary fat pad, and subrenal capsule. The engraftment of first-generation ovarian cancer PDXs usually takes 2-6. months. Success rates for first-generation ovarian cancer PDXs range from 25% to 80%, depending on many factors, including the type of immunocompromised mice, tumor histotypes, and implant sites. The ovarian cancer PDXs have been shown to retain the morphologic, immunophenotypic, and genomic characteristics of original human tumors. Moreover, the predictive value of ovarian cancer PDXs has been proved by recent studies that showed concordance between chemoresponse in tumor xenografts and patients.

KW - Mouse models

KW - Ovarian cancer

KW - Patient-derived xenograft

KW - Personalized therapy

KW - Preclinical models

UR - http://www.scopus.com/inward/record.url?scp=85020653666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020653666&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-804010-2.00019-9

DO - 10.1016/B978-0-12-804010-2.00019-9

M3 - Chapter

SN - 9780128040102

SP - 257

EP - 271

BT - Patient Derived Tumor Xenograft Models

PB - Elsevier Inc.

ER -